Model Information:

Castrate-resistant prostate cancer (CRPC); Recurrent chromosomal abnormalities included losses on chromosomes10q (includingPTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53), 18q, 3Mb deletion between ERG and TMPRSS2 on Ch21, 6q, and 9q. Gains included the q-arm of X,which was confirmed by PCR for ARTMPRSS-ETS fusion.

Summary

Cancer TypeProstate Cancer
SubtypeCRPC
GradeNA
StageM(b1)
EthnicityWestern
GenderM
Age67
Pathology Diagnosis

Castrate-resistant prostate cancer (CRPC); Recurrent chromosomal abnormalities included losses on chromosomes10q (includingPTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53), 18q, 3Mb deletion between ERG and TMPRSS2 on Ch21, 6q, and 9q. Gains included the q-arm of X,which was confirmed by PCR for ARTMPRSS-ETS fusion.

Biopsy Siteprimary
Treatment HistoryHT, CT
Pathology QCProstate cancer(PR6512-H149/5+C 10/1), poorly differentiated prostate adenocarcinoma; P504(+/-), 34bE12(nearly 1%: 1+), CK8(2+), PSA(<1%: 1+), Nkx3.1(2~3+), AR(3+), p63(2+)
Special FeaturesCRPC, model expansion is needed prio to study.
Mouse StrainRag2-/-?C-/-, NSG
TMANA
PublicationNA

Growth Characteristics

Additional Characteristics